^
Association details:
| Biomarker: | KIM1 expression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | CDX-014 (Microtubule inhibitor, TIM-1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Excerpt:
...Must have available tumor tissue for TIM-1 expression testing 6....
Trial ID:
Source:
Title:
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma
Published date:
05/29/2020
Excerpt:
CDX-014 showed antitumor activity with one prolonged partial response and a clinical benefit rate (objective response or stable disease >6 months) of 31%. The two patients that exhibited the most marked tumor shrinkage had high TIM-1 expression on tumor tissue.
DOI:
10.1007/s10637-020-00945-y
Trial ID:
Source:
Title:
Safety and efficacy of CDX-014, an antibody-drug conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced renal cell carcinoma
Excerpt:
Overall response rate was 6.25% with a partial response (PR) seen at 0.30 mg/kg dose lasting 21 months. Tumor shrinkage and progressive disease (PD) as best response occurred in 5 and 6 patients respectively. Clinical benefit rate (PR or Stable disease (SD) 6 months) was 25%. TIM-1 expression was noted in > 10% of tumor cells in 13 patients.
DOI:
10.1093/annonc/mdz249
Trial ID:
